Blue Owl Capital Holdings LP Increases Stock Holdings in Disc Medicine, Inc. (NASDAQ:IRON)

Blue Owl Capital Holdings LP increased its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 38.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 215,260 shares of the company’s stock after acquiring an additional 60,000 shares during the quarter. Disc Medicine makes up about 2.7% of Blue Owl Capital Holdings LP’s holdings, making the stock its 13th largest position. Blue Owl Capital Holdings LP owned about 0.87% of Disc Medicine worth $9,702,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Amalgamated Bank lifted its holdings in Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after acquiring an additional 247 shares during the period. Bleakley Financial Group LLC raised its stake in shares of Disc Medicine by 23.0% in the first quarter. Bleakley Financial Group LLC now owns 4,572 shares of the company’s stock valued at $285,000 after buying an additional 856 shares during the period. SG Americas Securities LLC raised its stake in shares of Disc Medicine by 44.2% in the second quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock valued at $183,000 after buying an additional 1,247 shares during the period. TD Asset Management Inc raised its stake in shares of Disc Medicine by 3.7% in the second quarter. TD Asset Management Inc now owns 40,732 shares of the company’s stock valued at $1,836,000 after buying an additional 1,468 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Disc Medicine by 66.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 4,641 shares of the company’s stock valued at $289,000 after buying an additional 1,848 shares during the period. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Stock Up 4.2 %

Disc Medicine stock opened at $50.07 on Friday. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60. The business has a 50-day simple moving average of $47.13 and a 200 day simple moving average of $42.71. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -14.81 and a beta of 0.59.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.08. On average, research analysts anticipate that Disc Medicine, Inc. will post -4.19 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IRON. Wells Fargo & Company began coverage on Disc Medicine in a research note on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research note on Friday, September 20th. BMO Capital Markets reiterated an “outperform” rating and set a $70.00 price objective (up from $50.00) on shares of Disc Medicine in a research note on Monday, June 17th. Wedbush reiterated an “outperform” rating and set a $57.00 price objective on shares of Disc Medicine in a research note on Friday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of Disc Medicine in a research note on Monday, September 16th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $64.13.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.